Yano, Seiji

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations

Yano, S., Wang, W., Li, Q., Matsumoto, K., Sakurama, H., Nakamura, T., Ogino, H., Kakiuchi, S., Hanibuchi, M., Nishioka, Y., et al. (2008) · Cancer Research

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 643

Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Wang, W., Li, Q., Yamada, T., Matsumoto, K., Matsumoto, I., Oda, M., Watanabe, G., Kayano, Y., Nishioka, Y., Sone, S., et al. (2009) · Clinical Cancer Research

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 297

Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS -Mutant Lung Cancer

Kitai, H., Ebi, H., Tomida, S., Floros, K. V., Kotani, H., Adachi, Y., Oizumi, S., Nishimura, M., Faber, A. C., & Yano, S. (2016) · Cancer Discovery

Lung Cancer Treatments and MutationsMelanoma and MAPK Pathways

Cited by 162

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Arasada, R. R., Shilo, K., Yamada, T., Zhang, J., Yano, S., Ghanem, R., Wang, W., Takeuchi, S., Fukuda, K., Katakami, N., et al. (2018) · Nature Communications

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 93

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J.-Y., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2023) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 53

Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer Cells Harboring RAS Mutations

Yamada, T., Amann, J. M., Tanimoto, A., Taniguchi, H., Shukuya, T., Timmers, C., Yano, S., Shilo, K., & Carbone, D. P. (2018) · Molecular Cancer Therapeutics

FOXO transcription factor regulationHistone Deacetylase Inhibitors Research

Cited by 44

AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells

Morimoto, K., Yamada, T., Hirai, S., Katayama, Y., Fukui, S., Sawada, R., Tachibana, Y., Matsui, Y., Nakamura, R., Ishida, M., et al. (2024) · Cancer Letters

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 20

Not just g RAS ping at flaws: Finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers

Ebi, H., Faber, A. C., Engelman, J. A., & Yano, S. (2014) · Cancer Science

Protein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases

Cited by 18